9-(1,2,3,4-Tetrahydro-naphthalen-1-yl)-1,9-dihydro-purin-6-one | 348627-46-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-(1,2,3,4-Tetrahydro-naphthalen-1-yl)-1,9-dihydro-purin-6-one
• 英文别名: 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1H-purin-6-one
• CAS: 348627-46-3
• 化学式: C₁₅H₁₄N₄O
• 分子量: 266.302
• InChiKey: WMJRQAGCTBOIEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  9-(1,2,3,4-Tetrahydro-naphthalen-1-yl)-1,9-dihydro-purin-6-one 在 溴 作用下， 以 水 为溶剂， 生成 8-Bromo-9-(1,2,3,4-tetrahydro-naphthalen-1-yl)-1,9-dihydro-purin-6-one
  参考文献：
  名称：

  Synthesis and structure–activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors

  摘要：

  The synthesis of a novel series of guanine analogues is reported. The compounds have been assessed in vitro and some analogues have been found to be inhibitors of phosphodiesterase type 7 (PDE7). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00125-1
• 作为产物：
  描述：

  6-chloro-9-(1,2,3,4-tetrahydronaphthalen-1-yl)-9H-purine 在 sodium hydroxide 作用下， 生成 9-(1,2,3,4-Tetrahydro-naphthalen-1-yl)-1,9-dihydro-purin-6-one
  参考文献：
  名称：

  Synthesis and structure–activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors

  摘要：

  The synthesis of a novel series of guanine analogues is reported. The compounds have been assessed in vitro and some analogues have been found to be inhibitors of phosphodiesterase type 7 (PDE7). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00125-1

文献信息

• USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN
  申请人：Cox Peter

  公开号：US20090111837A1

  公开（公告）日：2009-04-30

  The present invention relates to the use of a phosphodiesterase 7 (PDE7) inhibitor in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an inhibitor of PDE7.

  本发明涉及使用磷酸二酯酶7（PDE7）抑制剂制造治疗神经病理性疼痛药物以及使用PDE7抑制剂治疗神经病理性疼痛的方法。
• [EN] 9-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)-1,9-DIHYDROPURIN-6-ONE DERIVATIVES AS PDE7 INHIBITORS<br/>[FR] DERIVES DE 9-(1,2,3,4-TETRAHYDRONAPTHTHALENE-1-YLE)-1,9-DIHYDROPURINE-6-UN INHIBITEURS DE PDE7
  申请人：DARWIN DISCOVERY LTD

  公开号：WO2000068230A1

  公开（公告）日：2000-11-16

  Compounds of formula (i) wherein X-Y-Z represents NR4-C=N or N=C-NR4; R4, which can be attached to either X or Z, is a residue derived from 5,6,7,8- or 1,2,3,4-tetrahydro-naphthalene have therapeutic utility as inhibitors of PDE7.
• [EN] USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN<br/>[FR] UTILISATION DES INHIBITEURS DE PDE7 POUR LE TRAITEMENT DE LA DOULEUR NEUROPATHIQUE
  申请人：PFIZER LTD

  公开号：WO2006092691A1

  公开（公告）日：2006-09-08

  [EN] The present invention relates to the use of a phosphodiesterase 7 (PDE7) inhibitor in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an inhibitor of PDE7.
  [FR] La présente invention concerne l'utilisation d'un inhibiteur de la phosphodiestérase 7 (PDE7) dans la fabrication d'un médicament destiné au traitement de la douleur neuropathique, ainsi qu'un procédé de traitement de la douleur neuropathique au moyen d'un inhibiteur de PDE7.
• [EN] USE OF COMBINATIONS OF PDE7 INHIBITORS AND ALPHA-2-DELTY LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN<br/>[FR] UTILISATION D'ASSOCIATIONS D'INHIBITEURS DE PDE7 ET DE LIGANDS ALPHA-2-DELTA POUR LE TRAITEMENT DE LA DOULEUR NEUROPATHIQUE
  申请人：PFIZER LTD

  公开号：WO2006092692A1

  公开（公告）日：2006-09-08

  [EN] The instant invention relates to a combination of a PDE7 inhibitor and an alpha-2-delta ligand, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly inflammatory, neuropathic, visceral and nociceptive pain.
  [FR] La présente invention concerne une association d'un inhibiteur de PDE7 et d'un ligand alpha-2-delta ainsi que des sels pharmaceutiquement acceptables de ceux-ci, des compositions pharmaceutiques de ceux-ci et leur utilisation dans le traitement de la douleur, en particulier de la douleur inflammatoire, neuropathique, viscérale et nociceptive.